Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT05370755 Not yet recruiting - Clinical trials for Patients With Advanced Solid Tumors

A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors

Start date: May 31, 2022
Phase: Phase 1
Study type: Interventional

A Dose finding Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Preliminary Anti-Tumor Activity of ICP-189 Tablets and ICP-189 Tablets in Combination with Anti-PD-1 Monoclonal Antibody in Patients with Advanced Solid Tumors.

NCT ID: NCT05369286 Recruiting - Solid Tumor Clinical Trials

A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors

Start date: April 11, 2022
Phase: Phase 1
Study type: Interventional

This include two parts, part 1 is a dose escalation study and part 2 is a dose expansion study.

NCT ID: NCT05367778 Recruiting - Clinical trials for Advanced Solid Tumor

Phase 1/2 Study of HS-10370 in Patients With Advanced Solid Tumors

Start date: June 3, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

HS-10370 is an oral, highly selective, small molecular inhibitor of KRAS G12C. This study will evaluate the safety, tolerability, pharmacokinetics and clinical activity of HS-10370 in Chinese advanced solid tumor patients.

NCT ID: NCT05367635 Recruiting - Clinical trials for Advanced Solid Tumors

A Study of SKB315 in Patients With Advanced Solid Tumors

Start date: March 16, 2022
Phase: Phase 1
Study type: Interventional

This is a multicenter, open-label, multiple-dose dose finding and expansion study to evaluate the safety, tolerability, pharmacokinetic(PK) profile, and anti-tumor efficacy of SKB315 for injection in patients with advanced solid tumors.

NCT ID: NCT05367232 Recruiting - Clinical trials for Patients With Advanced Solid Tumors

A Study of ICP-033 in Patients With Advanced Solid Tumors

Start date: February 25, 2022
Phase: Phase 1
Study type: Interventional

A Dose finding Study to Evaluate the Safety, Tolerability and Pharmacokinetics and Preliminary Anti-Tumor Activity of ICP-033 Tablets in Patients with Advanced Solid Tumors.

NCT ID: NCT05364450 Active, not recruiting - Breast Cancer Clinical Trials

Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors

Start date: July 17, 2021
Phase: N/A
Study type: Interventional

Fear of cancer recurrence (FCR) is a highly prevalent, disruptive, and under-treated problem for breast cancer survivors. This randomized controlled trial will test the efficacy of group-based Acceptance and Commitment Therapy compared to Cognitive Behavioral Therapy and enhanced usual care for breast cancer survivors suffering from FCR while examining its cost-effectiveness and the mechanisms by which the intervention may work. Study findings will guide the future care of breast cancer survivors with FCR.

NCT ID: NCT05364359 Enrolling by invitation - Clinical trials for Hematological Malignancy

Individual Dietary Counseling Based on Taste-tests in Patients With Hematological Cancer in Cytostatic Therapy

HCP
Start date: March 28, 2022
Phase: N/A
Study type: Interventional

The purpose of the study is to investigate whether a simple taste-test will increase the intake of energy as part of the individual dietary counseling.

NCT ID: NCT05364086 Recruiting - Clinical trials for Malignant Solid Neoplasm

An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study

DiRECT
Start date: April 26, 2022
Phase:
Study type: Observational

This study compares treatment outcomes between patients of African American/Black (AA) ancestry and European American/White (EA) ancestry currently receiving immune checkpoint inhibitor treatment. Collecting samples of blood, saliva, stool, and health and treatment information from racially diverse patients receiving immune checkpoint inhibitor treatment over time may help doctors better understand healthcare disparities among all cancer patients.

NCT ID: NCT05361668 Active, not recruiting - Carcinoid Tumor Clinical Trials

Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome

Start date: June 17, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and exploratory dose response of paltusotine treatment in subjects with carcinoid syndrome. This study consists of a Randomized Treatment Phase followed by an Open-Label Extension (OLE) Phase.

NCT ID: NCT05360368 Not yet recruiting - Solid Tumor Clinical Trials

HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors

Start date: March 30, 2023
Phase: Phase 1
Study type: Interventional

This Phase1, open-label and dose-escalation study will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy of HLX07 administered as a single-agent by IV infusion every 3 weeks to patients with locally advanced or metastatic solid malignancies, who have failed or are intolerant to standard therapy, or for whom no standard therapy is available.